Compare Monster Beverage Corp (MNST) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Monster Beverage Corp trades at $43.6 (market cap $84.00B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Monster Beverage Corp and Regeneron Pharmaceuticals Inc are close in size by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MNST | REGN | |
|---|---|---|
Market Cap | $84.00B | $76.40B |
Volume | 8,371,981 | 626,381 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $852.03 |
52-Week Low | $33.16 | $557.73 |
Typical Hold Time | 72 Days | 107 Days |
Enterprise Value | $82.30B | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net income margin of 23.08%. Recent news highlights its debt-free balance sheet and international expansion, particularly a 35% surge in overseas sales.
The outlook is mixed: strong fundamentals and analyst consensus support upside to a $98.22 price target, but the stock faces headwinds from rich valuations (P/E 39.7) and technical bearishness. Key risks include inflation pressures and regulatory challenges, such as India's label ban. Institutional sentiment leans bullish, with 52% of analysts rating it Buy.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
